BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria
Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 26, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's...
BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes and overweight, non-obese individuals Preclinical data for BGM1812 supports...
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions...
NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
Highlights: NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease Treatment prevented hallmark developmental and morphological abnormalities, protected against...
Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS) rate of 74.2% DZD8586 exhibited significant antitumor...
JBD's ARTCs Image-Quality Engine Goes Commercial, Elevating Full-Color MicroLED Waveguide AR Glasses to an Unprecedented Visual Standard
SHANGHAI, June 4, 2025 /PRNewswire/ -- As a global leader in MicroLED microdisplay technology, JBD has announced that its proprietary, system-level image-quality engine for waveguide AR Glasses—ARTCs—has been fully integrated into RayNeo's flagship...
Orange completes successful trial of Fujitsu 1FINITY optical transport solution
Fujitsu 1FINITY T900 lab trial validates reduced cost per bit for more sustainable, high-performance, high-capacity networking KAWASAKI, Japan, June 4, 2025 /PRNewswire/ -- Fujitsu Limited announced that Orange S.A. successfully completed a lab...
e-STORAGE's SolBank 3.0 Successfully Passes Large-Scale Fire Testing (LSFT)
KITCHENER, ON, June 3, 2025 /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that e-STORAGE, which is part of the Company's majority-owned subsidiary CSI Solar Co., Ltd. ("CSI Solar"), has...
Self Storage Awards Asia Gala Dinner announces winners at Self Storage Expo Asia 2025
HONG KONG, June 3, 2025 /PRNewswire/ -- The Self Storage Association Asia announces the Self Storage Association Awards Asia 2025 winners in Tokyo. The Awards recognise Asia-wide and local excellence in self storage in customer service, the use of...
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
YANTAI, China, June 3, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating...